Stock comparison
Bausch Health Companies
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BHC
Bausch Health Companies
Market cap
$2.04B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BHC | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 50C | 66C | RPRX |
| Benjamin Graham | 18F | 84A | RPRX |
| Philip Fisher | 47D | 65C | RPRX |
| Peter Lynch | 17F | 60C | RPRX |
| Joel Greenblatt | 17F | 40D | RPRX |
| Charlie Munger | 56D | 68D | RPRX |
| Terry Smith | 49D | 58D | RPRX |
Side-by-side metrics
| Metric | BHC | RPRX |
|---|---|---|
| Market cap | $2.04B | $23.44B |
| P/E (TTM) | - | 27.6x |
| EV/EBIT | 9.7x | 19.9x |
| ROIC (TTM) | 11.59% | 8.43% |
| Gross margin | 61.67% | 99.95% |
| Net margin | -11.27% | 33.91% |
| Revenue CAGR 5y | 5.49% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | - | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BHC leads on
- Debt / Equity-vs 1.3x+113%
- P/E (TTM)-vs 27.6x+106%
- Revenue CAGR 5y5.49%vs 0.96%+83%
- EV/EBIT9.7xvs 19.9x+52%
RPRX leads on
- Net margin33.91%vs -11.27%+133%
- Dividend yield1.72%vs 0.0%+100%
- Market cap$23.44Bvs $2.04B+91%
- Gross margin99.95%vs 61.67%+38%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.